ChemicalBook > CAS DataBase List > Mycophenolate mofetil

Mycophenolate mofetil

Product Name
Mycophenolate mofetil
CAS No.
128794-94-5
Chemical Name
Mycophenolate mofetil
Synonyms
TM-MMF;Linfonex;RS 61443;Nsc724229;AKOS 92025;Mycophenolate;MYCOPHENLATE MOFETIL;Macophenolate Mofetil;Mofetil mycophenolate;Mycophenolate mofetil
CBNumber
CB5663336
Molecular Formula
C23H31NO7
Formula Weight
433.49
MOL File
128794-94-5.mol
More
Less

Mycophenolate mofetil Property

Melting point:
95-96°C
Boiling point:
637.6±55.0 °C(Predicted)
Density 
1.222±0.06 g/cm3(Predicted)
storage temp. 
room temp
solubility 
DMSO: ≥15mg/mL
form 
powder
pka
5.6(at 25℃)
color 
white to beige
Merck 
14,6327
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.
InChIKey
RTGDFNSFWBGLEC-SYZQJQIISA-N
CAS DataBase Reference
128794-94-5(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn
Risk Statements 
22
Safety Statements 
22-24/25
RIDADR 
UN 3077 9 / PGIII
WGK Germany 
3
RTECS 
MP7746700
HS Code 
29349990
Hazardous Substances Data
128794-94-5(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

H372Causes damage to organs through prolonged or repeated exposure

H410Very toxic to aquatic life with long lasting effects

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P273Avoid release to the environment.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
PHR1451
Product name
Mycophenolate Mofetil
Purity
Pharmaceutical Secondary Standard; Certified Reference Material
Packaging
1g
Price
$253
Updated
2024/03/01
Sigma-Aldrich
Product number
1448956
Product name
Mycophenolate mofetil
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$436
Updated
2024/03/01
TCI Chemical
Product number
M2387
Product name
Mycophenolate Mofetil
Purity
>98.0%(HPLC)(T)
Packaging
100mg
Price
$22
Updated
2024/03/01
TCI Chemical
Product number
M2387
Product name
Mycophenolate Mofetil
Purity
>98.0%(HPLC)(T)
Packaging
1g
Price
$42
Updated
2024/03/01
Cayman Chemical
Product number
13988
Product name
Mycophenolate Mofetil
Purity
≥95%
Packaging
50mg
Price
$45
Updated
2024/03/01
More
Less

Mycophenolate mofetil Chemical Properties,Usage,Production

Description

Mycophenolate mofetil was launched in 1995 in the U.S.A., its first market worldwide, for the prevention of acute kidney transplant rejection in conjunction with other immunosuppressive therapy and to treat refractory acute kidney graft rejection. With improved oral absorption and bioavailability, mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), a fermentation product of several Penicillium species. MPA is a selective, reversible, non-competitive inhibitor of inosinate dehydrogenase and guanylate synthetase. It inhibits the de now pathway of purine biosynthesis. MPA was found to have more potent antiproliferative effects on T and B lymphocytes than other cell types. Compared with other immunosuppressants, mycophenolate mofetil is reportedly superior due to its unique mechanism of action and excellent safety profile for long term use. Mycophenolate mofetil is being investigated clinically in the treatment of heart and liver transplantation rejection, asthma, in preventing coronary artery restenosis, and in treating rheumatoid arthritis.

Chemical Properties

White Powder

Originator

Roche (Switzerland)

Uses

An immunosuppressant.

Uses

For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.

Uses

Mycophenolate mofetil has been used to treat wild-type embryos for inhibiting nucleotide synthesis.

Definition

ChEBI: A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.

Indications

Mycophenolate mofetil (MMF, CellCept) is an ester prodrug of mycophenolic acid (MPA), a Penicillium-derived immunosuppressive agent that blocks de novo purine synthesis by noncompetitively inhibiting the enzyme inosine monophosphate dehydrogenase. MPA preferentially suppresses the proliferation of cells, such as T and B lymphocytes, that lack the purine salvage pathway and must synthesize de novo the guanosine nucleotides required for DNA and RNA synthesis.MPA has been used for decades as a systemic treatment for moderate to severe psoriasis. MMF was developed to increase the bioavailability of MPA.

Manufacturing Process

The synthesis of Mycophenolic acid (Canonica L. Et al., Tetrahedron Letters, 1971, N 28, p.2691-2692)
By condensation of sodium diethylmalonate and 3-methylpent-3-en-2-on in ethanol was obtained 2,3-dimethyl-4,6-dioxocyclohexanecarboxilic acid ethyl ester, which was aromatised to 4,6-dihydroxy-2,3-dimethylbenzoic acid ethyl ester (melting point 115-116°C). By treatment with diazomethane or with CH3I and K2CO3 this compound was transformed into 2,4-dimethoxy-5,6- dimethylbenzoic acid ethyl ester (melting point 62-63°C). The hydrolysis of the ester group furnished the 2,4-dimethoxy-5,6-dimethylbenzoic acid (melting point 208-210°C), which was converted into the amide: carbamic acid 3-methoxy-4,5,6-trimethylphenyl ester (melting point 225-229°C). Treatment of the amide with t-butylhypochlorite in methylene dichloride yielded the corresponding N-chloroamide which was photolysed to the intermediate iminolactone and was immediately hydrolized to 5,7-dimethoxy- 4-methyl-3H-isobenzofuran-1-one.
This compound with hydriodic acid in acetic acid in the presence of red phosphorous at reflux yielded 5,7-dihydroxy-4-methyl-3H-isobenzofuran-1- one. Condensation of 6-bromo-4-methylhex-4-enoic acid methyl ester and 5,7-dihydroxy-4-methyl-3H-isobenzofuran-1-one with silver oxide in dioxane at room temperature yielded 6-(4,6-dihydroxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid methyl ester (36% yield). At last, monomethylation with diazomethane yield 6-(4-hydroxy-6-methoxy-7- methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methylhex-4-enoic acid methyl ester, which was hydrolysed with aqueous sodium hydroxide to 6-(4- hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4- methylhex-4-enoic acid (Mycophenolic acid).
Mycophenolic acid may be obtained by the fermentation broth of Pennicillium brevicompactum. The synthesis of Mycophenolate mofetil (Patent U.S. 4,753,935). The mixture of Mycophenolic acid (32.0 g), thionyl chloride (25.0 ml) and DMF (0.3 ml) in dichloromethane (250 ml) was stirred at room temperature for 3 hours, after which the volatile components were removed under vacuum to afford mycophenolic acid chloride as an oil. The mycophenolic acid chloride oil was dissolved in dichloromethane (50.0 ml) and added to the chilled solution of morpholinoethanol (30.5 ml) in dichloromethane (250 ml). After stirring for 90 min at 4°C, the reaction mixture was washed with water and then with aqueous sodium bicarbonate. The organic solution was dried with sodium sulfate and evaporated to yield Mycophenolate mofetil: morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate (melting point 93-94°C).
The product (38.0 g) was dissolved in isopropanol (200 ml) and the solution was added to a solution of hydrogen chloride (10.0 g) in isopropanol (150 ml). The hydrochloride of Mycophenolate mofetil was collected by filtration and dried under vacuum (melting point 154-155°C).

brand name

CellCept

Therapeutic Function

Antiarthritic, Immunosuppressive

Biochem/physiol Actions

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

Mechanism of action

the guanosine nucleotides required for DNA and RNA synthesis.MPA has been used for decades as a systemic treatment for moderate to severe psoriasis. MMF was developed to increase the bioavailability of MPA.

Clinical Use

MMF is indicated for the prophylaxis of organ rejection in patients receiving renal, hepatic, and cardiac transplants; it is often used in combination with other immunosuppressive agents for this indication. In dermatology, MMF is particularly useful as monotherapy, or as a steroid-sparing agent, for treatment of autoimmune blistering diseases (bullous pemphigoid and pemphigus). It may also be useful for the treatment of inflammatory skin diseases mediated by neutrophilic infiltration, such as pyoderma gangrenosum, and psoriasis.

Side effects

Adverse effects produced by MMF most commonly include nausea, abdominal cramps, diarrhea, and possibly an increased incidence of viral and bacterial infections. Whether MMF may be associated with an increased long-term risk of lymphoma or other malignancies is controversial; however, any such risk is likely to be lower in patients treated for skin disease with MMF monotherapy than in transplant patients treated with combination immunosuppressive therapy.

Drug interactions

Potentially hazardous interactions with other drugs
Antipsychotics: avoid with clozapine (increased risk of agranulocytosis).
Antivirals: higher concentrations of both mycophenolate and aciclovir or ganciclovir when the two are prescribed concomitantly
. Antacids: absorption of mycophenolate decreased in presence of magnesium and aluminium salts. Antibacterials: bioavailability of mycophenolate possibly reduced by metronidazole and norfloxacin; concentration of active metabolite reduced by rifampicin.
Colestyramine: 40% reduction in oral bioavailability of mycophenolate.
Ciclosporin: some studies show that ciclosporin decreases plasma MPA AUC levels; other studies show increases - no dose change required.
Iron preparations: may significantly reduce absorption of mycophenolate.
Sevelamer: reduced levels of mycophenolate.
Tacrolimus: increases MPA concentrations- no dose change required but monitor closely.
See 'Other information'

Metabolism

Mycophenolate undergoes presystemic metabolism in the liver to active mycophenolic acid (MPA). MPA undergoes enterohepatic recirculation and secondary increases in plasma MPA concentrations are seen; these have been reported at between 6-12 hours after a dose of mycophenolate mofetil, and at between 6-8 hours after a dose of mycophenolate sodium. MPA is metabolised by glucuronidation to the inactive mycophenolic acid glucuronide. The majority of a dose of mycophenolate is excreted in the urine as this glucuronide, with negligible amounts of MPA; about 6% of a dose is recovered in faeces.

storage

Store at RT

References

1) Allison and Eugui (1996), Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF); Clin. Transplant., 10 77 2) Jonsson et al. (2002), Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages; Cell. Immunol., 216 93 3) Allison et al. (1993), Mechanisms of action of mycophenolic acid; Ann. NY Acad. Sci., 696 63 4) Quemeneur et al. (2002), Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis; J. Immunol., 169 2747 5) Ebrahimi et al. (2012) Time dependent neuroprotection of mycophenolate mofetil; effects on temporal dynamics in glial proliferation, apoptosis, and scar formation; J. Neuroinflammation, 9 89

Mycophenolate mofetil Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Mycophenolate mofetil Suppliers

Jai Radhe Sales
Tel
+(91)-(79)-26431096/65255722
Fax
+(91)-(79)-26569884
Email
info@jairadhesales.com
Country
India
ProdList
397
Advantage
60
GLR Innovations
Tel
+91 9891111994
Email
info@glrgroup.in
Country
India
ProdList
4535
Advantage
58
TCI Chemicals (India) Pvt. Ltd.
Tel
--
Fax
--
Email
sales-in@tcichemicals.com
Country
India
ProdList
6768
Advantage
58
Jigs chemical
Tel
--
Fax
--
Email
info@jigschemical.com
Country
India
ProdList
318
Advantage
58
CLEANCHEM LABORATORIES LLP
Tel
--
Fax
--
Email
sales4@cleanchemlab.com
Country
India
ProdList
325
Advantage
58
Triveni chemicals
Tel
--
Fax
--
Email
sales@trivenichemical.com
Country
India
ProdList
6088
Advantage
58
Concord Biotech Limited
Tel
--
Fax
--
Country
India
ProdList
8
Advantage
58
Anant Pharmaceuticals Pvt. ltd
Tel
--
Fax
--
Email
info@anantlabs.com
Country
India
ProdList
736
Advantage
58
Nakshatra Chemicals
Tel
--
Fax
--
Country
India
ProdList
162
Advantage
58
Globofarm International Private Limited
Tel
--
Fax
--
Email
procurement@globofarm.net
Country
India
ProdList
188
Advantage
58
Rakshit Group of Companies
Tel
--
Fax
--
Email
sales@rakshitdrugspvtltd.com
Country
India
ProdList
16
Advantage
58
Athos Chemicals
Tel
--
Fax
--
Email
export@athoschemicals.com
Country
India
ProdList
315
Advantage
58
Novas International
Tel
--
Fax
--
Email
info@novasinternational.com
Country
India
ProdList
210
Advantage
58
Ayon PharmaChem
Tel
--
Fax
--
Email
bhargav@ayonpharmachem.com
Country
India
ProdList
303
Advantage
58
Camus Pharma
Tel
--
Fax
--
Email
business@camuspharma.com
Country
India
ProdList
46
Advantage
58
Pharma Affiliates
Tel
--
Fax
--
Email
@pharmaffiliates.com
Country
India
ProdList
6754
Advantage
58
Pharmaffiliates Analytics & Synthetics (P) Ltd.
Tel
--
Fax
--
Email
g@pharmaffiliates.com
Country
India
ProdList
631
Advantage
58
BDR Pharmaceuticals International Pvt., Ltd.
Tel
--
Fax
--
Email
marketing@bdrpharma.com
Country
India
ProdList
91
Advantage
58
Oceanic Pharmachem Pvt., Ltd. (OPPL)
Tel
--
Fax
--
Email
info@oceanicpharmachem.com
Country
India
ProdList
946
Advantage
58
Humble Healthcaare Limited
Tel
--
Fax
--
Email
export@humblehealthcaare.com
Country
India
ProdList
63
Advantage
58
Aadivighnesh Chem Private Ltd.
Tel
--
Fax
--
Email
sales@aadivighnesh.com
Country
India
ProdList
119
Advantage
58
International Drug & Chemical Co.
Tel
--
Fax
--
Email
sales@idcco.com
Country
India
ProdList
65
Advantage
58
Avanscure Lifesciences Private Limited
Tel
--
Fax
--
Country
India
ProdList
66
Advantage
58
Anzen Exports
Tel
--
Fax
--
Email
info@anzen.co.in
Country
India
ProdList
164
Advantage
58
Gemini Exports
Tel
--
Fax
--
Email
uiry@geminiexpor
Country
India
ProdList
140
Advantage
58
Cleargreens Pharmaceutical Private Limited
Tel
--
Fax
--
Email
info@cleargreenspharma.com
Country
India
ProdList
13
Advantage
58
Orbit Lifescience Pvt., Ltd.
Tel
--
Fax
--
Email
orbit@orbitlifescience.com
Country
India
ProdList
206
Advantage
58
Sumar Biotech Llp
Tel
--
Fax
--
Country
India
ProdList
12
Advantage
58
Sign Pharma Trade Services Pvt., Ltd.(SPTS)
Tel
--
Fax
--
Email
info@signpharma.com
Country
India
ProdList
160
Advantage
58
Samchem India
Tel
--
Fax
--
Email
varun@samchem.in
Country
India
ProdList
48
Advantage
58
Festiva Pharma
Tel
--
Fax
--
Country
India
ProdList
237
Advantage
58
Opulent Pharma
Tel
--
Fax
--
Country
India
ProdList
810
Advantage
58
Viraj Pharmaceuticals Pvt. Ltd.
Tel
--
Fax
--
Email
virajppl@gmail.com
Country
India
ProdList
162
Advantage
58
Innorex Pharmaceuticals Private Limited
Tel
--
Fax
--
Email
info@innorexpharma.com
Country
India
ProdList
173
Advantage
58
Novorix Pharma Pvt. Ltd.
Tel
--
Fax
--
Email
info@novorixpharma.com
Country
India
ProdList
47
Advantage
58
Clearsynth Labs
Tel
--
Fax
--
Email
fo@clearsynth.com
Country
India
ProdList
3887
Advantage
58
Pharma Links
Tel
--
Fax
--
Email
info@pharmalinksindia.com
Country
India
ProdList
85
Advantage
58
Disha APIs Pvt Ltd
Tel
--
Fax
--
Email
info@dishaapis.com
Country
India
ProdList
90
Advantage
58
Gliesse Pharmaceuticals Pvt., Ltd.
Tel
--
Fax
--
Email
info@gliessepharma.com
Country
India
ProdList
165
Advantage
58
SRINI PHARMACEUTICALS PRIVATE LTD
Tel
--
Fax
--
Email
info@srinipharma.com
Country
India
ProdList
36
Advantage
58
Dharmanandan Export Pvt., Ltd.
Tel
--
Fax
--
Email
info@dnexport.com
Country
India
ProdList
161
Advantage
58
Manus Aktteva Biopharma LLP
Tel
--
Fax
--
Country
India
ProdList
655
Advantage
58
Besil Chem LLP
Tel
--
Fax
--
Email
info@besilchem.com
Country
India
ProdList
65
Advantage
58
Vyshno Bio Sciences
Tel
--
Fax
--
Email
info@vyshnobio.com
Country
India
ProdList
239
Advantage
58
Avance Healthcare Pvt., Ltd.
Tel
--
Fax
--
Email
info@avancehealthcare.com
Country
India
ProdList
17
Advantage
58
Symbio Generics India Private Limited
Tel
--
Fax
--
Email
info@coperniciumpharma.com
Country
India
ProdList
1
Advantage
58
Aligns International
Tel
--
Fax
--
Email
info@aligns.in
Country
India
ProdList
137
Advantage
58
SOLARA ACTIVE PHARMA SCIENCES LTD
Tel
--
Fax
--
Email
info@solara.co.in
Country
India
ProdList
89
Advantage
58
SynZeal Research Pvt Ltd
Tel
--
Fax
--
Email
standards@synzeal.com
Country
India
ProdList
6514
Advantage
58
RPG Life Sciences Limited
Tel
--
Fax
--
Email
info@rpglifesciences.com
Country
India
ProdList
13
Advantage
58
More
Less

View Lastest Price from Mycophenolate mofetil manufacturers

shandong perfect biotechnology co.ltd
Product
Mycophenolate mofetil 128794-94-5
Price
US $0.00/KG
Min. Order
1KG
Purity
98% HPLC
Supply Ability
200kg
Release date
2023-11-16
Wuhan Senwayer Century Chemical Co.,Ltd
Product
Mycophenolate mofetil 128794-94-5
Price
US $0.00/mg
Min. Order
100mg
Purity
99%
Supply Ability
50kg
Release date
2023-02-08
Jinan Shengqi pharmaceutical Co,Ltd
Product
Mycophenolate Mofetil 128794-94-5
Price
US $0.00/kg
Min. Order
1kg
Purity
98
Supply Ability
10MT
Release date
2019-03-06

128794-94-5, Mycophenolate mofetilRelated Search:


  • 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate
  • 2-morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate
  • 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-m
  • (4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-morpholin-4-ylethyl ester
  • Linfonex
  • 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
  • (E)-2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-m
  • 2-morpholin-4-ylethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-isobenzofuran-5-yl)-4-methyl-hex-4-enoate
  • AKOS 92025
  • 6-[(7-hydroxy-5-methoxy-4-methyl-1-oxo-3h-isobenzofuran-6-yl)]-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester
  • (4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester
  • 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
  • 2-morpholin-4-ylethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
  • 2-morpholin-4-ylethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
  • 2-(4-Morpholinyl)ethyl ester
  • Mycophenolate mofetil, 98%, a reversible inhibitor of (IMPDH1/2)
  • 4-HEXENOIC ACID,6-(1,3-DIHYDRO-4-HYDROXY-6-METHOXY-7-METHYL-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-,2-(4-MORPHOLINYL)ETHYL ESTER
  • Mycophenolate
  • MYCOPHENLATE MOFETIL
  • Macophenolate Mofetil
  • MycophenolicAcid-2-(4-Morpholinyl)ethylEster
  • (4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)4-hexenoic Acid 4-methyl-2-(4-morpholinyl)ethyl Ester
  • RS 61443
  • TM-MMF
  • Mycophenolate Mofetil (CellCept)
  • (E)-2-Morpholinoethyl 6-(4-hydroxy-6-Methoxy-7-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-Methylhex-4-enoate
  • (E)-4-Methyl-6-[(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran)-5-yl]-4-hexenoic acid 2-morpholinoethyl ester
  • (E)-6-[(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran)-5-yl]-4-methyl-4-hexenoic acid 2-morpholinoethyl ester
  • Mofetil mycophenolate
  • 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
  • Nsc724229
  • Mycophenolate mofetil
  • 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoicacid2-(4-morpholinyl)ethylester
  • Mycophenolate Mofetil (200 mg)
  • (E)-2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-meth
  • 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
  • MycophenolateMofetil&gt
  • (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Morpholinyl)ethyl Ester
  • 2-(4-Morpholinyl)ethyl (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate
  • Mycophenolate mofetil ISO 9001:2015 REACH
  • Mycophenolic Acid 2-Morpholinoethyl Ester
  • Mycophenolate mofetil for peak identification (Y0000519)
  • Mycophenolate MofetilQ: What is Mycophenolate Mofetil Q: What is the CAS Number of Mycophenolate Mofetil Q: What is the storage condition of Mycophenolate Mofetil Q: What are the applications of Mycophenolate Mofetil
  • TIANFUCHEM--128794-94-5---Mycophenolate mofetil
  • Mycophenolate Mofetil (1448956)
  • Mycophenolate mofetil (RS-61443)
  • 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
  • 2- (Morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3- oxo-1,3- dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
  • Mycophenolate Mofetil 6-[(7-Hydroxy-5-methoxy-4-methyl-1-oxo-3H-isobenzofuran-6- yl)]-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester
  • Mycophenolate mofetil, MPDH inhibitor
  • 128794-94-5
  • 128791-94-5
  • C23H31NO7
  • Anti-cancer&immunity
  • Inhibitor
  • Immunosuppressant
  • antibiotic
  • Pharmaceutical material and intermeidates